Toronto Dominion Bank Sells 10,181 Shares of Insulet Co. (NASDAQ:PODD)

Toronto Dominion Bank lowered its position in Insulet Co. (NASDAQ:PODD) by 26.0% in the 1st quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The fund owned 28,965 shares of the medical instruments supplier’s stock after selling 10,181 shares during the period. Toronto Dominion Bank’s holdings in Insulet were worth $4,965,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Other institutional investors have also added to or reduced their stakes in the company. Orion Portfolio Solutions LLC lifted its stake in Insulet by 276.6% in the fourth quarter. Orion Portfolio Solutions LLC now owns 10,221 shares of the medical instruments supplier’s stock worth $2,069,000 after purchasing an additional 7,507 shares during the last quarter. Asset Management One Co. Ltd. lifted its stake in Insulet by 33.7% in the fourth quarter. Asset Management One Co. Ltd. now owns 36,677 shares of the medical instruments supplier’s stock worth $8,048,000 after purchasing an additional 9,240 shares during the last quarter. Aquila Investment Management LLC bought a new stake in Insulet in the fourth quarter worth about $1,302,000. SG Americas Securities LLC lifted its stake in Insulet by 349.3% in the first quarter. SG Americas Securities LLC now owns 29,575 shares of the medical instruments supplier’s stock worth $5,069,000 after purchasing an additional 22,993 shares during the last quarter. Finally, Allianz Asset Management GmbH lifted its stake in Insulet by 85.1% in the fourth quarter. Allianz Asset Management GmbH now owns 108,109 shares of the medical instruments supplier’s stock worth $23,457,000 after purchasing an additional 49,715 shares during the last quarter.

Insider Activity

In other news, SVP Mark N. Field sold 1,500 shares of the business’s stock in a transaction on Friday, June 14th. The shares were sold at an average price of $199.96, for a total transaction of $299,940.00. Following the sale, the senior vice president now directly owns 12,875 shares of the company’s stock, valued at $2,574,485. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through this link. In other news, SVP Mark N. Field sold 1,500 shares of the business’s stock in a transaction on Friday, June 14th. The shares were sold at an average price of $199.96, for a total transaction of $299,940.00. Following the sale, the senior vice president now directly owns 12,875 shares of the company’s stock, valued at $2,574,485. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through this link. Also, Director Timothy J. Scannell sold 7,000 shares of the business’s stock in a transaction on Monday, June 10th. The shares were sold at an average price of $190.51, for a total transaction of $1,333,570.00. Following the sale, the director now directly owns 35,586 shares in the company, valued at $6,779,488.86. The disclosure for this sale can be found here. Insiders have sold 13,931 shares of company stock valued at $2,636,286 over the last ninety days. 0.47% of the stock is currently owned by insiders.

Insulet Price Performance

NASDAQ PODD opened at $193.30 on Friday. The firm’s fifty day simple moving average is $193.24 and its two-hundred day simple moving average is $184.60. The company has a current ratio of 3.74, a quick ratio of 2.75 and a debt-to-equity ratio of 1.72. Insulet Co. has a 12-month low of $125.82 and a 12-month high of $283.00. The firm has a market capitalization of $13.54 billion, a P/E ratio of 58.58, a P/E/G ratio of 3.48 and a beta of 1.16.

Insulet (NASDAQ:PODD) last released its quarterly earnings results on Thursday, May 9th. The medical instruments supplier reported $0.73 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.39 by $0.34. The business had revenue of $441.70 million for the quarter, compared to analyst estimates of $424.05 million. Insulet had a net margin of 13.14% and a return on equity of 34.06%. The business’s revenue for the quarter was up 23.3% on a year-over-year basis. During the same period in the previous year, the company earned $0.23 earnings per share. Analysts forecast that Insulet Co. will post 3.11 EPS for the current fiscal year.

Analyst Ratings Changes

Several analysts have issued reports on PODD shares. Canaccord Genuity Group reissued a “buy” rating and issued a $234.00 price objective on shares of Insulet in a research note on Tuesday, July 23rd. Raymond James decreased their price target on shares of Insulet from $218.00 to $213.00 and set an “outperform” rating for the company in a research note on Friday, May 10th. Redburn Atlantic assumed coverage on shares of Insulet in a research note on Thursday, May 30th. They set a “buy” rating and a $235.00 price target for the company. Jefferies Financial Group lifted their price target on shares of Insulet from $255.00 to $260.00 and gave the company a “buy” rating in a research note on Friday, May 10th. Finally, Barclays decreased their price target on shares of Insulet from $213.00 to $200.00 and set an “equal weight” rating for the company in a research note on Monday, May 13th. Four analysts have rated the stock with a hold rating and fifteen have given a buy rating to the stock. According to MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and an average target price of $239.18.

About Insulet

Insulet Corporation develops, manufactures, and sells insulin delivery systems for people with insulin-dependent diabetes. The company's Omnipod platform includes the Omnipod 5 Automated Insulin Delivery System (Omnipod 5) which includes a proprietary AID algorithm embedded in the Pod that integrates with a third-party continuous glucose monitor to obtain glucose values through wireless bluetooth communication; Omnipod DASH that features a bluetooth enabled Pod that is controlled by a smartphone-like Personal Diabetes Manager with a color touch screen user interface; and Omnipod GO, a standalone, wearable, insulin delivery system that provides a fixed rate of continuous rapid-acting insulin for 72 hours.